four most common serotypes 6B, 14, 19F, and 23F pre-vaccination, 1, 3, 6, 9 , and 12 months after the last dose of PCV13 were performed. Achievement of significant antibody response was defined as greater than equal to twofold increase in the IgG level.
Results. From January 2016 to December 2017, a total of 72 patients were randomized to receive one (n = 35) or two doses (n = 37) PCV13. Of all, 31 patients (43%), including one dose in 14 and two doses in 17, had completed 12-month follow-up with a median age of 62 years old . Sequential changes of significant antibody responses to serotype 6B, 14, 19F, and 23F during 1-year follow-up in one and two does groups are presented in Figure 1 . The proportions of significant antibody responses to serotype 6B, 14, 19F, and 23F after 1-year follow-up were 33.3, 25.0, 41.7, and 41.7% in one dose group and 11.8, 35.3, 29.4, and 23 .5% in two-dose group, respectively.
Conclusion. Two-dose PCV13 did not provide better immunogenicity to patients with MM. Innovative strategies to improve the immunogenicity of PCV13 in patients with MM are needed. Figure 1 : Sequential changes of significant antibody responses to serotype 6B, 14, 19F, and 23F during 1-year follow-up in one-and two-dose groups. Background. Diabetes, a prevalent chronic condition in younger adults, increases the risk of pneumonia. The incidence of pneumonia hospitalization among adults aged <65 years with diabetes is comparable to that of the overall population aged ≥65 years. While 13-valent conjugate pneumococcal vaccination (PCV13) is routinely recommended for adults aged ≥65 years, it has not been recommended for younger adults with diabetes. We modeled the potential impact of PCV13 use in this population.
Disclosures
Methods. We estimated the cumulative number of pneumonia hospitalizations and hospital days potentially averted with PCV13 use in adults aged <65 years with diabetes over 5 years in the United States. Model inputs are summarized in Table 1 . We ran multiple scenarios depending on a number of vaccine efficacy/effectiveness (VE) estimates. We estimated the number of hospitalizations averted as the product of (i) the size of the target population, (ii) the incidence of all-cause CAP, (iii) the proportion of CAP that is PCV13 type, (iv) PCV13 effectiveness, and (v) the duration of protection for PCV13 over a 5-year time horizon. Number-needed-to-vaccinate (NNV) for each scenario was also assessed.
Results. Roughly 15 million adults aged <65 years have diabetes in the United States, accounting for about 250,000 pneumonia hospitalizations annually. Based on published, US estimates of pneumonia incidence and PCV13 etiology, PCV13 vaccination in this population could avert 24,638-44,506 hospitalizations and 206,955-373,854 hospital days over a 5-year period. NNV to avert one hospitalization and one hospital day were 344-622 and 41-74, respectively.
Conclusion. PCV13 vaccination of younger adults with diabetes could reduce a substantial number of pneumonia hospitalizations. NNV is comparable to those for adults aged ≥65 years, for whom PCV13 is currently recommended. Background. In Portugal, following the use of PCVs in children, there were major changes in the serotype distribution of the pneumococcal population in adult pneumococcal invasive disease (IPD). The inclusion of PCV13 in the National Immunization Plan in 2015 could have an even greater impact on adult IPD. To evaluate this, we monitored the serotypes and antimicrobial resistance of invasive pneumococcal isolates in 2015-2017.
Methods. A total of 1,495 adult IPD isolates were recovered, serotyped by Quellung and tested for susceptibility to antimicrobials by disk diffusion or Etest.
Results. The number of isolates recovered in each year remained approximately constant. Among the 1,495 isolates, 58 different serotypes were found and only a small proportion of these were nontypeable (0.6%, n = 9). The most common were serotypes 8 (18%), 3 (15%), 22F and 14 (7% each), 19A (6%) , and 20 (4%). The majority of isolates expressed serotypes exclusively found in the 23-valent polysaccharide vaccine (41%, n = 619). A considerable number of isolates expressed PCV serotypes (n = 563), of which 207 isolates (14%) expressed PCV7 serotypes and the remaining isolates expressed the additional serotypes included in PCV13 (n = 356, 24%). Non-vaccine types (NVT) were found in 313 isolates (n = 21%) and among these, serotypes 6C, 15A, 16F, 23A and 31 were the most prevalent, together accounting for approximately half of the NVT. Overall, 19% of the isolates presented resistance to erythromycin and penicillin nonsusceptibility was found in 17% of the isolates recovered in 2015-2017.
Conclusion. After several years of pneumococcal conjugate vaccines use in children, PCV serotypes are still frequently responsible for adult IPD. Moreover, serotypes exclusively found in PPV23 were also found to be important causes of invasive disease in this period, suggesting an important role for vaccination in disease prevention in this age group. 
